藥明康德(02359.HK):美國生物安全法案草案內容既不恰當也不準確
藥明康德(02359.HK)公布,有關一項於上周四(25日)提交給美國眾議院的《生物安全法案》法案草案版本中提及公司,惟該等內容既不恰當也不準確。
公司堅信其業務不會對任何國家的國家安全構成風險;並未贊助過以軍民融合為主題的會議或者其他活動;從未收到過任何軍民融合基金的直接投資,亦不會收到該等二級市場投資者的投資資金;「藥明康德生命化學研究獎」的客觀評選標準僅與科研經驗、科研能力及科研成果相關,並不會就任何候選人的背景或者就職單位而給予特別考慮。
截至目前,公司生產經營活動正常,日常經營情況未發生重大變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.